Heatwurx (PCSA) Projected to Post Quarterly Earnings on Thursday

by · The Markets Daily

Heatwurx (NASDAQ:PCSA – Get Free Report) is projected to issue its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect the company to announce earnings of ($1.50) per share for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 26, 2026 at 4:00 PM ET.

Heatwurx Stock Performance

Shares of NASDAQ:PCSA opened at $3.12 on Tuesday. The firm has a market cap of $7.08 million, a PE ratio of -0.09 and a beta of 1.05. The firm’s 50 day simple moving average is $2.77 and its 200-day simple moving average is $5.04. Heatwurx has a one year low of $1.76 and a one year high of $19.64.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on PCSA shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Heatwurx in a research note on Thursday, January 22nd. Wall Street Zen lowered Heatwurx from a “hold” rating to a “sell” rating in a research report on Saturday, February 14th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Heatwurx currently has a consensus rating of “Hold” and an average target price of $25.00.

Get Our Latest Analysis on PCSA

Heatwurx Company Profile

(Get Free Report)

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.

Featured Articles